Analyst Price Targets — GDRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 20, 2026 6:57 pm | — | Barclays | $4.00 | $3.56 | TheFly | GoodRx price target raised to $4 from $3 at Barclays |
| August 13, 2026 12:08 pm | — | UBS | $3.75 | $3.60 | TheFly | GoodRx price target raised to $3.75 from $2.50 at UBS |
| August 7, 2026 10:28 am | — | Goldman Sachs | $4.00 | $3.72 | TheFly | GoodRx price target raised to $4 from $3.50 at Goldman Sachs |
| August 6, 2026 5:52 pm | — | Leerink Partners | $5.00 | $3.73 | TheFly | GoodRx price target raised to $5 from $3.50 at Leerink |
| May 8, 2026 11:57 am | Eric Sheridan | Goldman Sachs | $3.50 | $2.84 | TheFly | GoodRx price target raised to $3.50 from $2.50 at Goldman Sachs |
| February 26, 2026 6:08 pm | Michael Cherny | Leerink Partners | $3.00 | $2.02 | StreetInsider | GoodRx Holdings Inc. (GDRX) PT Lowered to $3 at Leerink Partners |
| January 22, 2026 6:00 am | Glen Santangelo | Jefferies | $2.75 | $2.58 | StreetInsider | Jefferies Downgrades GoodRx Holdings Inc. (GDRX) to Hold |
| December 18, 2025 12:54 pm | — | Morgan Stanley | $4.00 | $2.78 | TheFly | GoodRx price target lowered to $4 from $5 at Morgan Stanley |
| December 8, 2025 9:14 pm | — | Barclays | $3.00 | $2.72 | TheFly | GoodRx initiated with an Underweight at Barclays |
| August 11, 2025 11:01 am | George Hill | Deutsche Bank | $6.00 | $3.47 | TheFly | GoodRx price target lowered to $6 from $8 at Deutsche Bank |
Latest News for GDRX
GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating.
GoodRx CEO Wendy Barnes discusses the company's partnership with TrumpRx and efforts to lower prescription drug costs on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #clamancountdown #goodrx #trumprx #wendybarnes #prescriptiondrugs #drugprices #healthcare #health #medicine #pharmacy #patients #consumer #trump #donaldtrump #donald_trump
GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript
GoodRx NASDAQ: GDRX reported second-quarter 2026 revenue of $200.4 million and adjusted EBITDA of $63.7 million, representing a 31.8% adjusted EBITDA margin, as growth in its Pharma Direct and subscription businesses offset pressure in prescription transaction revenue.
The latest earnings from Oscar Health and GoodRx show both companies dealing with a changing customer base. The former company reported half-year earnings Thursday (Aug. 6) showing record profitability for the first six months of 2026, with revenues surging 70% to $4.9 billion.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GDRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.